TTX-siPDL1 / TransCode - LARVOL DELTA

Cancer immunotherapy based on the RNAi-based PD-L1 inhibitor, MN-siPDL1, demonstrates efficacy in preclinical pancreatic adenocarcinoma (AACR 2023) - "To overcome these challenges, here we describe the preclinical testing of a new checkpoint inhibitor named MN-siPDL1 in combination with gemcitabine in an aggressive model of PDAC. Finally, as an initial measurement of tissue damage due to the treatment, we analyzed major organs by histopathology and saw no differences from the vehicle-treated controls. Considering the aggressive and fibrous nature of the Hy15549 model and its resistance to traditional checkpoint inhibitors, the described RNAi-based therapeutic approach could be promising against PDAC and could make an impact on one of the most intractable cancers which has long evaded the power of modern medicine to deliver long-term survival."

IO biomarker • Preclinical • Tumor mutational burden • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • TMB

TransCode Therapeutics to present at AACR Annual Meeting 2023 (GlobeNewswire) - "TransCode Therapeutics...announced that it will present new results and a clinical study overview at the Phase I and First-in-Human Clinical Trials in Progress Session at the 2023 American Association of Cancer Research (AACR) Annual Meeting to be held April 14-19. Studies to be highlighted as part of the Meeting’s Poster Sessions include: A study of the Company’s RNAi-based checkpoint inhibitor, TTX-siPDL1, in preclinical animal models of pancreatic adenocarcinoma indicating successful delivery, pharmacodynamic activity, and therapeutic efficacy. The study represents a collaboration between TransCode Therapeutics and the Athinoula A. Martinos Center for Biomedical Imaging and the Division of Gastrointestinal and Oncologic Surgery at the Massachusetts General Hospital and Harvard Medical School."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma (GlobeNewswire) - "TransCode Therapeutics, Inc...reported positive preclinical results with its immunotherapy candidate, TTX-siPDL1, in pancreatic adenocarcinoma....After two weekly treatments with TTX-siPDL1 combined with the standard-of-care chemotherapeutic, gemcitabine, tumor volumes were 25% of those in untreated animals. By the fifth week of treatment, 75% of animals treated with TTX-siPDL1 plus gemcitabine were still alive versus 25% of those that were treated with gemcitabine alone....'Recent updates to our company website include an animation that showcases our delivery platform as well as the MOA of our lead therapeutic candidate, TTX-MC138'."

Pipeline update • Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update (GlobeNewswire) - "Planned Milestones...Publication of preclinical results supporting therapeutic candidate, TTX-RIGA; Continuation of preclinical studies for therapeutic candidates TTX-RIGA, TTX-siPDL1, and TTX-siLIN28B....Research and development expense was $1.9 million in the first quarter of 2022, compared to $0.3 million in the first quarter of 2021."

Commercial • Preclinical • Oncology